Clinical trial NCT04140552: Chinese Research Group of Gallbladder Cancer
Official title: Chinese Research Group of Gallbladder Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Gallbladder Neoplasms
Keywords: gallbladder neoplasms
gallbladder cancer
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Anhui Medical University
name: Anhui Provincial Hospital
name: The First Affiliated Hospital of Bengbu Medical University
name: LanZhou University
name: Henan Cancer Hospital
name: The First Affiliated Hospital of Zhengzhou University
name: The Second Affiliated Hospital of Harbin Medical University
name: First Affiliated Hospital of Harbin Medical University
name: Harbin Medical University
name: The First Hospital of Jilin University
name: Second Hospital of Jilin University
name: China-Japan Union Hospital, Jilin University
name: The First People's Hospital of Changzhou
name: Changzhou No.2 People's Hospital
name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
name: The First People's Hospital of Taicang
name: Wuxi Second People's Hospital
name: Xuzhou Central Hospital
name: Second Affiliated Hospital of Suzhou University
name: Affiliated Hospital of Nantong University
name: The First People's Hospital of Nantong
name: The Affiliated Hospital of Xuzhou Medical University
name: Second Affiliated Hospital of Nanchang University
name: The First Affiliated Hospital of Nanchang University
name: Jiangxi Provincial People's Hopital
name: Shengjing Hospital
name: Baotou Central Hospital
name: Qinghai People's Hospital
name: Changzhi Medical College
name: The First Affiliated Hospital of Shanxi Medical University
name: Shanxi Provincial Cancer Hospital
name: First Affiliated Hospital Xi'an Jiaotong University
name: Eastern Hepatobiliary Surgery Hospital
name: Shanghai Fengxian District Central Hospital
name: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
name: Shanghai Zhongshan Hospital
name: Shanghai Pudong Hospital
name: Central Hospital of Minhang District, Shanghai
name: Putuo District People's Hospital of Shanghai
name: Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
name: Tianjin Medical University Cancer Hospital
name: First Affiliated Hospital of Xinjiang Medical University
name: First Affiliated Hospital of Kunming Medical University
name: Yinzhou Hospital Affiliated to Medical School of Ningbo University
name: Shaoxing Second Hospital
name: Shaoxing People's Hospital
name: First Affiliated Hospital of Wenzhou Medical University
name: Sir Run Run Shaw Hospital
name: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: Zhejiang Cancer Hospital
name: Huizhou Municipal Central Hospital
name: Ningbo No. 1 Hospital
name: People's Hospital of Hunan Province
name: Hainan People's Hospital
name: Taizhou Hospital
name: Xinghua City People's Hospital
name: Tongliao City Hospital
name: Jiangxi Provincial Cancer Hospital
name: Shandong Provincial Hospital
name: Qilu Hospital of Shandong University
name: The Affiliated Hospital of Qingdao University
name: Xijing Hospital
First posted: 2019-10-28
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from 2008 to 2020 diagnosed with gallbladder cancer in collaborated hospitals in China.

Brief summary: The Chinese Research Group of Gallbladder Cancer (CRGGC) is a retrospective multicenter registry cohort, collecting electronic medical records of patients diagnosed with gallbladder cancer from hospitals in collaboration.

Detailed description: The objectives of the CRGGC are as follows:

1. To study the current diagnosis and treatment of gallbladder cancer in China.
2. To clarify the prognostic role of debated risk factors associated with gallbladder cancer.
3. To improve the accurate staging of gallbladder cancer.
4. To standardize the treatment with gallbladder cancer.

Eligibility criteria: Inclusion Criteria:

* Patients with at least clinical diagnosis of gallbladder cancer, including C23.9 and part of C24.0 (cystic duct cancer).
* Patients with accessible electronic medical record

Exclusion Criteria:

* Patients with undetermined primary site of cancer.

Primary outcomes:
measure: Overall Survival
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
state: Anhui
city: Hefei
country: China
facility: Anhui Provincial Hospital
state: Anhui
city: Hefei
country: China
facility: The First Affiliated Hospital of Anhui Medical University
state: Anhui
city: Harbin
country: China
facility: The First Affiliated Hospital of Harbin Medical University
state: Heilongjiang
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
state: Heilongjiang
city: Harbin
country: China
facility: The Second Affiliated Hospital of Harbin Medical University
state: Heilongjiang
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Zhengzhou
country: China
facility: The Fifth Affiliated Hospital of Zhengzhou University
state: Henan
city: Changsha
country: China
facility: People's Hospital of Hunan Province
state: Hunan
city: Baotou
country: China
facility: Baotou City Central Hospital
state: Inner Mongolia
city: Changshu
country: China
facility: Changshu No.1 People's Hospital
state: Jiangsu
city: Changzhou
country: China
facility: Changzhou No.2 People's Hospital
state: Jiangsu
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
state: Jiangsu
city: Nantong
country: China
facility: The First People's Hospital of Nantong
state: Jiangsu
city: Nantong
country: China
facility: Affiliated Hospital of Nantong University
state: Jiangsu
city: Nantong
country: China
facility: Nantong Tumor Hospital
state: Jiangsu
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Suzhou University
state: Jiangsu
city: Taicang
country: China
facility: The First People's Hospital of Taicang
state: Jiangsu
city: Wuxi
country: China
facility: Wuxi Second People's Hospital
state: Jiangsu
city: Xuzhou
country: China
facility: The Affiliated Hospital of Xuzhou Medical University
state: Jiangsu
city: Xuzhou
country: China
facility: Xuzhou Central Hospital
state: Jiangsu
city: Nanchang
country: China
facility: Jiangxi Provincial People's Hospital
state: Jiangxi
city: Nanchang
country: China
facility: The Second Affiliated Hospital of Nanchang University
state: Jiangxi
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
state: Jiangxi
city: Changchun
country: China
facility: The First Bethune Hospital of Jilin University
state: Jilin
city: Changchun
country: China
facility: China-Japan Union Hospital of Jilin University
state: Jilin
city: Changchun
country: China
facility: The Second Hospital of Jilin University
state: Jilin
city: Gansu
country: China
facility: The First Hospital of Lanzhou University
state: Lanzhou
city: Shenyang
country: China
facility: Shengjing Hospital of China Medical University
state: Liaoning
city: Xining
country: China
facility: Qinghai Provincial People's Hospital
state: Qinghai
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xi'an Jiaotong University
state: Shaanxi
city: Shanghai
country: China
facility: Zhongshan Hospital
state: Shanghai
city: Shanghai
country: China
facility: Putuo District People's Hospital of Shanghai
state: Shanghai
city: Shanghai
country: China
facility: Shanghai General Hospital
state: Shanghai
city: Shanghai
country: China
facility: Xinhua Hospital
state: Shanghai
city: Shanghai
country: China
facility: Eastern Hepatobiliary Surgery Hospital
state: Shanghai
city: Shanghai
country: China
facility: Central Hospital of Minhang District
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Pudong Hospital
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Fengxian District Central Hospital
state: Shanghai
city: Shanghai
country: China
facility: Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
state: Shanghai
city: Changzhi
country: China
facility: Heping Hospital Affiliated to Changzhi Medical College
state: Shanxi
city: Taiyuan
country: China
facility: First Hospital of Shanxi Medical University
state: Shanxi
city: Taiyuan
country: China
facility: Shanxi Provincial Cancer Hospital
state: Shanxi
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Hospital
state: Tianjin
city: Ürümqi
country: China
facility: The First Affiliated Hospital of Xinjiang Medical University
state: Xinjiang
city: Kunming
country: China
facility: The First Affiliated Hospital of Kunming Medical University
state: Yunnan
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of medicine
state: Zhejiang
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital
state: Zhejiang
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
city: Huzhou
country: China
facility: Huzhou Central Hospital
state: Zhejiang
city: Ningbo
country: China
facility: Ningbo First Hospital
state: Zhejiang
city: Ningbo
country: China
facility: Yinzhou Hospital Affiliated to Medical School of Ningbo University
state: Zhejiang
city: Shaoxing
country: China
facility: Shaoxing People's Hospital
state: Zhejiang
city: Shaoxing
country: China
facility: Shaoxing Second Hospital
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
Study officials:
affiliation: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
name: Yingbin Liu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Li L, Ren T, Liu K, Li ML, Geng YJ, Yang Y, Li HF, Li XC, Bao RF, Shu YJ, Weng H, Gong W, Lau WY, Wu XS, Liu YB. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Front Oncol. 2021 Jun 29;11:692647. doi: 10.3389/fonc.2021.692647. eCollection 2021.
citation: Ren T, Li Y, Zhang X, Geng Y, Shao Z, Li M, Wu X, Wang XA, Liu F, Wu W, Shu Y, Bao R, Gong W, Dong P, Dang X, Liu C, Liu C, Sun B, Liu J, Wang L, Hong D, Qin R, Jiang X, Zhang X, Xu J, Jia J, Yang B, Li B, Dai C, Cao J, Cao H, Tao F, Zhang Z, Wang Y, Jin H, Cai H, Fei Z, Gu J, Han W, Feng X, Fang L, Zheng L, Zhu C, Wang K, Zhang X, Li X, Jin C, Qian Y, Cui Y, Xu Y, Wang X, Liu H, Hua Y, Liu C, Hao J, Wang C, Li Q, Li X, Liu J, Li M, Qiu Y, Wu B, Zheng J, Chen X, Zhu H, Hua K, Yan M, Wang P, Zang H, Ma X, Hong J, Liu Y. Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. BMJ Open. 2021 Feb 16;11(2):e038634. doi: 10.1136/bmjopen-2020-038634.